{"preliminary_commentary":{"by_channel":{"x_thread":4,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05306340","nct_id":"NCT05306340","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05306340. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Giredestrant plus Everolimus","type":"EXPERIMENTAL"},{"description":"The physician's choice of endocrine therapy is defined as either exemestane, fulvestrant, or tamoxifen.","label":"Physician's Choice of Endocrine Therapy plus Everolimus","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-10-15","type":"ESTIMATED"},"conditions":["Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer"],"enrollment":{"count":373,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Giredestrant","otherNames":["GDC-9545","RO7197597","RG6171"],"type":"DRUG"},{"name":"Exemestane","otherNames":[],"type":"DRUG"},{"name":"Fulvestrant","otherNames":[],"type":"DRUG"},{"name":"Tamoxifen","otherNames":[],"type":"DRUG"},{"name":"Everolimus","otherNames":[],"type":"DRUG"},{"name":"LHRH Agonist","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone Mouth Rinse","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-17","lead_sponsor":"Genentech, Inc.","official_title":"A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival, as Determined by the Investigator According to RECIST v1.1, in the ESR1m Subpopulation and ITT Population","timeFrame":"From randomization until the first occurrence of disease progression or death from any cause, whichever occurs first (up to 42 months)"}],"references":[{"citation":"Mayer EL, Tolaney SM, Martin M, Vidal GA, Moscetti L, Jhaveri KL, Brufsky A, Gradishar WJ, Schneeweiss A, Niikura N, Favret A, Alfie M, Lee KS, Khan S, Feldman MB, Day BM, Lam LH, Darbonne WC, Shah MD, Griffiths KL, DiLallo G, Perez-Moreno PD, Rugo HS; evERA Breast Cancer Investigators. Giredestrant plus Everolimus in Advanced Breast Cancer. N Engl J Med. 2026 Oct 1;395(13):1285-1298. doi: 10.1056/NEJMoa2602457.","pmid":"42814929","type":"DERIVED"}],"start_date":{"date":"2022-08-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","url":"https://clinicaltrials.gov/study/NCT05306340"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05306340"}